[CAS NO. 152-62-5] Dydrogesterone

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [152-62-5]

Catalog

HY-B0257A

Brand

MCE

CAS

152-62-5

DESCRIPTION [152-62-5]

Overview

MDL	-
Molecular Weight	312.45
Molecular Formula	C21H28O2
SMILES	CC([C@H]1CC[C@@]2([H])[C@]3([H])C=CC4=CC(CC[C@@]4(C)[C@]3([H])CC[C@]12C)=O)=O

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]Cells. 2022, 11(3), 319.

Summary

Dydrogesterone is a potent, orally active progestogen indicated in a wide variety of gynaecological conditions related to progesterone deficiency.

IC50 & Target

Progesterone Receptor ^[1] .

In Vitro

Dydrogesterone is a potent, orally active progestogen indicated in a wide variety of gynaecological conditions related to progesterone deficiency. Although similar in molecular structure and pharmacological effects to endogenous progesterone. It is orally active at far lower doses. Its freedom from estrogenic, androgenic, anabolic, corticoid and other undesirable hormonal effects gives it additional benefits over most other synthetic progestogens.Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counteract the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05135013	NewGiza University\|Ain Shams University	Observational Study	November 16, 2021
NCT03998761	M? ??c Hospital	Infertility	June 26, 2019	Not Applicable
NCT04788108	Chulalongkorn University	Threatened Abortion	August 1, 2021	Phase 4
NCT02128685	The University of Hong Kong	Pregnancy	March 2016	Phase 3
NCT03690765	Abbott	Endometriosis	September 27, 2018
NCT03790215	Peking Union Medical College Hospital	Endometrial Polyp	February 1, 2019	Phase 4
NCT03859921	The University of Hong Kong	Subfertility	July 1, 2021	Phase 3
NCT03935152	Chulalongkorn University	Preterm Labor	May 11, 2019	Phase 4
NCT03267771	Assiut University	Abortion in First Trimester	October 1, 2017	Phase 4
NCT01178931	University of Zagreb	Luteal Phase Defect	October 2010	Not Applicable
NCT03832699	Wolfson Medical Center	ART	March 1, 2019	Not Applicable
NCT05112692	Mansoura University	PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries	November 2021	Not Applicable
NCT00251082	Solvay Pharmaceuticals	Postmenopause	December 2005	Phase 3
NCT02921763	Mylan Inc.\|Viatris Inc.	Endometriosis	August 23, 2016
NCT02989519	Sanpasitthiprasong Hospital	Preterm Delivery	August 2015	Phase 3
NCT05577806	Clinica de la Mujer Medicina Reproductiva, Chile	Infertility, Female\|Fertility Disorders	January 1, 2017
NCT04758871	CRG UZ Brussel	Frozen Embryo Transfer\|Hormone Replacement Therapy\|Dydrogesterone\|Infertility, Female	March 1, 2021	Phase 4
NCT03428685	The University of Hong Kong	Preterm Birth	January 15, 2019	Phase 2\|Phase 3
NCT03677336	CRG UZ Brussel\|Universitätsklinikum Hamburg-Eppendorf\|Abbott\|KU Leuven	Infertility, Female\|Infertility\|Genital Diseases, Male\|Genital Diseases, Female\|Progesterone\|Dydrogesterone\|Hormones\|Hormones, Hormone Substitutes, and Hormone Antagonists\|Physiological Effects of Drugs\|Progestins	May 1, 2019	Phase 4
NCT04175990	National University of Malaysia	IVF\|Oocyte Maturation Defect 1\|Clinical Pregnancy Rate\|Ovarian Hyperstimulation	May 10, 2018	Phase 1
NCT03537287	Ain Shams University	Preterm Labor	July 2016	Phase 2
NCT02620345	Trieu, Nguyen Thi, M.D.	Fibroids	January 2010	Phase 4
NCT02086032	Chiang Mai University	Menopausal and Postmenopausal Disorders	January 2014	Not Applicable
NCT01850030	Abbott\|Quintiles, Inc.	Female Infertility	August 2013	Phase 3
NCT02262481	Chulalongkorn University	Preterm Labor	August 2014	Not Applicable
NCT04124913	Memorial Sisli Hospital, Istanbul	Infertility, Female\|Infertility, Male\|Embryo Transfer\|Fertilization in Vitro\|Drug Effect\|Reproductive Techniques, Assisted\|Progesterone\|Dydrogesterone	January 2, 2019	Phase 4
NCT04287205	Kanuni Sultan Suleyman Training and Research Hospital	Endometriosis\|Sexual Dysfunction	April 20, 2019	Not Applicable
NCT03309735	Besins Healthcare\|Clinical Research Laboratory, CRO, Russia	Threatened Miscarriage	October 16, 2017
NCT03675139	Xiaojun Chen\|Fudan University	Endometrial Hyperplasia Without Atypia	February 26, 2019	Phase 2\|Phase 3
NCT05569577	Fudan University	Luteal Phase Deficiency\|Luteal Phase Support\|Idiopathic Hypogonadotropic Hypogonadism	January 1, 2021	Not Applicable
NCT02706470	Fudan University	Miscarriage, Recurrent	May 2016	Phase 2\|Phase 3
NCT03456570	Assiut University	Functional Ovarian Cyst\|Progesterone	May 1, 2018	Early Phase 1
NCT04408144	Laniado Hospital	Infertility\|IVF	April 1, 2022	Not Applicable
NCT03948022	Centrum Clinic IVF Center	Implantation; Placenta\|Pregnancy Loss\|Frozen Embryo\|Luteal Support\|Luteal Phase Defect\|Assisted Reproduction	June 30, 2021	Phase 4
NCT02990403	Shanghai First Maternity and Infant Hospital	Recurrent Pregnancy Loss	October 2014	Phase 4
NCT05300841	Sohag University	PCOS\|ICSI	May 1, 2022	Early Phase 1
NCT00160316	Solvay Pharmaceuticals	Postmenopause	April 2005	Phase 3
NCT02491437	Abbott\|PRA Health Sciences\|Datamap	Female Infertility	July 2015	Phase 3
NCT03329898	Beijing Obstetrics and Gynecology Hospital	Intrauterine Adhesion	October 31, 2017	Not Applicable
NCT00193674	Abbott Products\|Abbott	Recurrent Miscarriage	September 2003	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 33.33 mg/mL ( 106.67 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.2005 mL	16.0026 mL	32.0051 mL
5 mM	0.6401 mL	3.2005 mL	6.4010 mL
10 mM	0.3201 mL	1.6003 mL	3.2005 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Dydrogesterone, From Wikipedia, the free encyclopedia

Synonyms

Pregna-4,6-diene-3,20-dione, (9β,10α)-

9β,10α-Pregna-4,6-diene-3,20-dione

(9β,10α)-Pregna-4,6-diene-3,20-dione

6-Dehydro-9β,10α-progesterone

6α-Dehydro-retro-Δ⁴-pregnene-3,20-dione

6-Dehydroretroprogesterone

Diphaston

Dydrogesterone

Hydrogesterone

Retro-6-dehydroprogesterone

Retroprogesterone, 6-dehydro-

Terolut

Isopregnenone

Δ⁶-Retroprogesterone

Duphaston

Gestatron

Prodel

Retrone

Dufaston

Duvaron

Gynorest

NSC 92336